GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Karuna Therapeutics
The historical chart of Karuna, the biotech company that achieved a breakthrough in schizophrenia treatment with its drug KarXT, reflected this remarkable success. Its story culminated in its acquisition by Bristol Myers Squibb in 2024.
Share prices of companies in the market segment - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company that has developed an innovative drug for the treatment of schizophrenia with a novel mechanism of action. We have classified it under "Pharma: Psycho." The chart below shows how investors value breakthrough technologies in psychiatry.
Broad Market Index - GURU.Markets
Karuna Therapeutics is a biotech company that has developed an innovative drug for the treatment of schizophrenia. As a pioneer in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Karuna shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
KRTX - Daily change in the company's share price Karuna Therapeutics
Karuna Therapeutics' daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its psychosis treatments.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Before its acquisition by Bristol Myers Squibb, Karuna Therapeutics was a biopharmaceutical company with a breakthrough drug for schizophrenia. Its story exemplifies a huge success story in biotech. The chart below illustrates the volatility of a sector where a single successful drug can lead to a multi-billion dollar deal.
Daily change in the price of a broad market stock, index - GURU.Markets
Karuna Therapeutics is a biotech company developing psychedelic-based drugs. News of clinical trials in this cutting-edge field triggers sharp stock price movements, which, in turn, contribute to the overall "noise" and market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Karuna Therapeutics
Karuna Therapeutics' year-to-date performance tells the story of its breakthrough in schizophrenia treatment. Its 12-month market cap growth reflects successful clinical trials and FDA approval of its drug KarXT, as well as its recent acquisition by Bristol Myers Squibb, one of the biggest biopharma events of the year.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Karuna, a biotech company, developed a breakthrough drug for the treatment of schizophrenia. Its acquisition by Bristol Myers Squibb was a recognition of its scientific success. Its past performance reflected both the risks of clinical trials and the enormous potential of its drug.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Karuna Therapeutics, a biopharmaceutical company that has developed a potentially revolutionary drug for the treatment of schizophrenia, is one of the most striking success stories in biotech. Its year-over-year market capitalization reflects the high expectations surrounding the drug's commercial launch.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Karuna Therapeutics
Karuna, a biopharmaceutical company, achieved a breakthrough in the treatment of schizophrenia. Its monthly performance reflected stellar clinical trial results. This rapid growth culminated in the announcement of its acquisition by Bristol Myers Squibb, which anchored its final valuation.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new drugs for the treatment of psychiatric and neurological disorders. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its lead drug, which has the potential to become a new standard of treatment for schizophrenia, toward the market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Karuna Therapeutics is a biopharmaceutical company focused on psychiatry. Its shares are buoyed by anticipation of clinical trial results. Their monthly performance is completely disconnected from the market, as the chart clearly illustrates, showing a reaction to scientific data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Karuna Therapeutics
Karuna Therapeutics, a biopharmaceutical company focused on psychiatry, is experiencing high volatility. Its weekly stock price is driven by news of clinical trials of its schizophrenia drugs, reflecting hopes for a breakthrough in this complex field.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Karuna Therapeutics shares, like those of the entire psychiatric biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major trial can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Karuna Therapeutics is a biotech company focused on psychiatry. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that KRTX's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
KRTX - Market capitalization of the company Karuna Therapeutics
Karuna Therapeutics' stock chart is a financial map of a breakthrough in schizophrenia treatment. Its high market cap reflects the enormous expectations for its new drug, which has shown impressive results in clinical trials. Its performance is a barometer of expectations for one of the most significant new psychiatric drugs in decades.
KRTX - Share of the company's market capitalization Karuna Therapeutics within the market segment - Pharma psycho
Karuna Therapeutics is developing a new generation of drugs for the treatment of psychiatric and neurological disorders. Its significant market cap reflects high expectations for its lead drug. The company's size is a bet on a breakthrough in the treatment of schizophrenia and other serious illnesses.
Market capitalization of the market segment - Pharma psycho
Karuna Therapeutics develops drugs to treat psychoses, including schizophrenia. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect the urgent need for new, more effective antipsychotic drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Karuna Therapeutics has achieved a breakthrough in the treatment of schizophrenia with its new drug. Its market capitalization chart is a story of great scientific success. Its performance relative to the market reflects the enormous value the market places on this new approach to treating severe mental illnesses.
Book value capitalization of the company, segment and market as a whole
KRTX - Book value capitalization of the company Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company. Its book value represents its R&D capital. The chart below shows its vast financial resources, especially after successful trials, to prepare for the commercialization of a new schizophrenia drug.
KRTX - Share of the company's book capitalization Karuna Therapeutics within the market segment - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company developing treatments for mental disorders. Its core capital is intellectual property. Its share of physical assets will be minimal, reflecting a focus on research rather than large manufacturing facilities.
Market segment balance sheet capitalization - Pharma psycho
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Karuna, which develops drugs for the treatment of psychosis, looks "light." Its value lies in its pipeline of promising developments and patents, not in its ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Karuna Therapeutics is a biotech company that has successfully developed a new drug for schizophrenia. Its assets are not its factories, but the patent for this breakthrough drug. The company's balance sheet represents the value of hope for millions of people suffering from severe mental illness and enormous commercial potential in the real world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Karuna Therapeutics
Karuna's balance sheet consists of its cash and the patent for a breakthrough schizophrenia drug. Its market capitalization represents a huge valuation for a future blockbuster. The MvsBCap_Co chart shows how many times the "dream" of a single, revolutionary drug could be worth compared to all the company's assets.
Market to book capitalization ratio in a market segment - Pharma psycho
Karuna Therapeutics has achieved success in developing a new drug for the treatment of schizophrenia. The chart shows the enormous market premium placed on its scientific breakthrough, reflecting the drug's enormous potential to become a new standard in psychiatry.
Market to book capitalization ratio for the market as a whole
Karuna Therapeutics is developing psychotropic drugs with a novel mechanism of action. The company's success could change approaches to schizophrenia treatment. Its market valuation reflects this enormous potential. The chart shows how much investors are willing to pay for the promise of a breakthrough in psychiatry, yielding a valuation that is a multiple of its book value.
Debts of the company, segment and market as a whole
KRTX - Company debts Karuna Therapeutics
Karuna Therapeutics, a biopharmaceutical company, is using capital to bring its innovative drug for schizophrenia to market. This chart shows how the company prepares for commercial launch, which requires significant investments in marketing and sales. Debt or equity is the final step in turning science into product.
Market segment debts - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company that has successfully developed a new drug for the treatment of schizophrenia. This chart illustrates the company's financial position as it transitions from clinical development to commercialization, when investments in marketing and manufacturing are required.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company that has successfully developed a drug for the treatment of schizophrenia. This chart shows its financial position from development to commercialization. It reflects how the company manages capital after successful trials, preparing for a large-scale launch.
Market segment debt to market segment book capitalization - Pharma psycho
Karuna Therapeutics has succeeded in developing a new drug for the treatment of schizophrenia. Bringing such a blockbuster to market requires enormous marketing and production costs. The chart shows how the company's debt burden compares to its overall market capitalization and financial standards in the pharmaceutical industry.
Debt to book value of all companies in the market
Karuna Therapeutics (KRTX) is a biopharmaceutical company developing drugs for the treatment of psychiatric and neurological diseases. This chart shows the overall debt burden of the economy. It serves as a contrast to Karuna's financial model, which relies on equity capital during clinical trials, avoiding debt risk before commercialization.
P/E of the company, segment and market as a whole
P/E - Karuna Therapeutics
This metric for Karuna Therapeutics reflects the enormous expectations surrounding its schizophrenia drug. The very high P/E (or lack thereof) is based on the drug's potential to become a blockbuster. The company's valuation is a bet on the successful approval and commercial launch of one of the most anticipated drugs in psychiatry.
P/E of the market segment - Pharma psycho
This chart shows the average P/E valuation for biotech companies. For Karuna, with its potential blockbuster treatment for schizophrenia, this is an important benchmark. A P/E higher than the average would reflect the high investor expectations for one of the most promising drugs in modern psychiatry.
P/E of the market as a whole
Karuna Therapeutics, acquired by Bristol Myers Squibb, developed a breakthrough drug, KarXT, for the treatment of schizophrenia with a novel mechanism of action. This is one of the most significant developments in psychiatry in recent decades. This chart shows the mood in biotech. Karuna's success is a story of pure scientific breakthrough, independent of general market trends and transforming the entire industry.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company that has successfully developed a new drug for the treatment of schizophrenia. This chart reflects analyst expectations regarding the commercial potential of this breakthrough drug. It shows the market's anticipated future sales and profits following successful clinical trials.
%20P%2FE%20Karuna%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Karuna-Therapeutics&v=1772648044867 "Chart of the company's future (projected) P/E Karuna Therapeutics")
Future (projected) P/E of the market segment - Pharma psycho
Karuna Therapeutics is developing drugs to treat psychosis associated with schizophrenia and Alzheimer's disease. This chart shows average expectations for the pharmaceutical sector. KRTX's position may indicate the level of investor confidence in its lead drug candidate, which could be a breakthrough in the treatment of these complex mental disorders.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772648044878 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Karuna Therapeutics develops drugs for the treatment of psychosis. Given the huge unmet need in this area, the company's success depends on clinical data. Overall market sentiment in this chart influences the sector, but a breakthrough in schizophrenia treatment will be the primary driver.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648044890 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company developing drugs for the treatment of psychiatric and neurological disorders. This chart reflects a breakthrough in the treatment of psychosis. Revenue trends will be driven by the success of its lead drug, KarXT, for schizophrenia, which has shown promising results and is targeting a huge market.
Profit of companies in the market segment - Pharma psycho
Karuna Therapeutics develops drugs to treat psychosis associated with schizophrenia and Alzheimer's disease. Profitability in the psychopharmacology sector, as this chart shows, is driven by the need for new, more effective treatments. The success of KRTX with its innovative approach could be the first major breakthrough in schizophrenia treatment in decades, bringing hope to millions.
Overall market profit
Karuna Therapeutics, a biopharmaceutical company focused on treating psychosis, is developing drugs for a huge market with unmet needs. Its success depends on regulatory approval and physician acceptance, not the economic cycle shown by this chart. The need for effective treatments for mental disorders is constant.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Karuna Therapeutics
Karuna Therapeutics develops innovative drugs for the treatment of psychoses, particularly schizophrenia. This chart reflects analyst forecasts, which are betting on the success of its lead drug, which has the potential to change the standard of treatment for mental disorders.
%20profit%20of%20the%20company%20Karuna%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Karuna-Therapeutics&v=1772648044982 "Graph of future (projected) profit of the company Karuna Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma psycho
Karuna Therapeutics develops innovative drugs for the treatment of mental illnesses, particularly schizophrenia. Its key drug, KarXT, has a novel mechanism of action distinct from existing antipsychotics. This chart shows the revenue forecast for the psychopharmaceutical sector, reflecting the urgent need for breakthrough treatments for mental disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772648045021 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Karuna Therapeutics is a biopharmaceutical company developing drugs for the treatment of mental disorders. Its success is determined by clinical trial results and regulatory approvals. The overall economic outlook influences it indirectly, through investor willingness to finance risky projects and the ability of the healthcare system to pay for new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648045035 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Karuna Therapeutics
Karuna Therapeutics achieved a breakthrough in the treatment of schizophrenia with its new drug. Despite having no significant revenue prior to its launch, its valuation on this chart reflected the market's enormous expectations. Investors were assessing not current sales, but the drug's potential to become a multi-billion-dollar blockbuster and change the standard of care in psychiatry.
P/S market segment - Pharma psycho
Karuna Therapeutics develops drugs to treat psychoses in conditions such as schizophrenia and Alzheimer's disease by targeting new neural pathways. The chart shows the average revenue estimate for the biotech company, providing insight into how investors value its innovative approach to treating severe mental disorders.
P/S of the market as a whole
Karuna Therapeutics is a biopharmaceutical company whose lead drug has demonstrated breakthrough results in the treatment of schizophrenia. Its success could change the standard of care. A graph of average market revenue estimates shows that the company's price reflects high expectations for bringing a new blockbuster to market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company developing drugs to treat psychiatric and neurological disorders. The chart shows high market expectations for its lead product. It values the company based on potential future revenue from its new class of antipsychotic drugs, which could become a blockbuster.
%20P%2FS%20Karuna%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Karuna-Therapeutics&v=1772648045139 "The graph of the company's future (projected) P/S Karuna Therapeutics")
Future (projected) P/S of the market segment - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company developing treatments for psychosis associated with schizophrenia and Alzheimer's disease. This chart shows the average future sales estimates for companies in its core business. It provides context for understanding how the market views the commercial potential of its lead drug, KarXT, which could become a new standard of care.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772648045164 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Karuna Therapeutics developed drugs to treat mental disorders. Its value was based on the potential of its lead drug. This overall revenue expectation schedule was irrelevant. Investors were focused entirely on clinical trial results that could lead to a breakthrough in the treatment of schizophrenia.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648045214 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of psychiatric and neurological disorders. Being in clinical development, it typically does not generate sales revenue. This chart will show the future commercial success of its drugs after their potential regulatory approval.
Sales of companies in the market segment - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of mental illnesses, primarily schizophrenia. Their lead candidate is based on a novel mechanism of action that could improve tolerability. This chart shows the sector's total revenue, reflecting the enormous need for new and more effective treatments for psychosis.
Overall market sales
Karuna Therapeutics is a biopharmaceutical company specializing in the treatment of mental disorders. Its market capitalization depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to finance risky projects in the field of psychopharmacology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Karuna Therapeutics
Karuna Therapeutics, now part of Bristol Myers Squibb, has developed a breakthrough drug for schizophrenia with a novel mechanism of action. Sales expectations for this drug are enormous, as it could change the standard of care. This chart reflects the commercial success forecasts for this potential blockbuster.
%20sales%20of%20the%20company%20Karuna%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Karuna-Therapeutics&v=1772648045291 "Schedule of future (projected) sales of the company Karuna Therapeutics")
Future (projected) sales of companies in the market segment - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of mental illnesses, primarily schizophrenia. Its lead drug has shown promising results. The chart shows forecasts for the psychopharmacology sector. Karuna's success could lead to a breakthrough in the treatment of these complex disorders.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772648045311 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Karuna Therapeutics develops innovative drugs for the treatment of psychoses, particularly schizophrenia. The company's success depends on clinical trial results and regulatory approval. This schedule, reflecting the overall investment climate, affects the availability of funding for breakthrough, yet risky, developments in psychiatry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648045340 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of mental disorders, particularly schizophrenia. The company is in late-stage clinical trials. This chart shows the financial trajectory of the company as it approaches the potential commercialization of its breakthrough drug.
Market segment marginality - Pharma psycho
Karuna Therapeutics develops medications for the treatment of mental illnesses, with a focus on schizophrenia. This chart shows the average profitability in the pharmaceutical industry. The potentially breakthrough mechanism of action of its lead drug could allow the company to capture significant market share and achieve exceptional profitability.
Market marginality as a whole
Karuna Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of psychiatric and neurological disorders. Its lead drug targets schizophrenia. Being in late-stage development, it demonstrates a path from scientific hypothesis to potential blockbuster, which contrasts with the average profitability of established companies.
Employees in the company, segment and market as a whole
Number of employees in the company Karuna Therapeutics
Karuna Therapeutics achieved a breakthrough in the treatment of schizophrenia with its new drug. This chart shows how the company rapidly expanded its team. This expansion, particularly in the clinical and commercial departments, was necessary to conduct final trials and prepare for the blockbuster's market launch.
Share of the company's employees Karuna Therapeutics within the market segment - Pharma psycho
Karuna Therapeutics achieved a breakthrough in the treatment of schizophrenia by developing a new drug with a unique mechanism of action. The company's success is a credit to its focused scientific team. This chart shows the percentage of leading neuropsychiatric experts Karuna attracted, which enabled its success, leading to its acquisition by the pharmaceutical giant Bristol Myers Squibb.
Number of employees in the market segment - Pharma psycho
Karuna Therapeutics, Inc. is a biopharmaceutical company developing innovative drugs for the treatment of psychosis. The rapid growth of its clinical and commercial team, visible in the graph, is due to successful trial results and preparations for the launch of its lead drug. The staff increase is a sign of imminent commercialization.
Number of employees in the market as a whole
Karuna Therapeutics, acquired by Bristol Myers Squibb, achieved a breakthrough in schizophrenia treatment with its new drug. The growth of its team in this graph reflects its journey from an R&D startup to a blockbuster company. The increase in staff, particularly in the clinical and commercial departments, was a direct result of its success, which attracted the attention of Big Pharma.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Karuna Therapeutics (KRTX)
Karuna Therapeutics is a biopharmaceutical company focused on treating mental disorders (schizophrenia). Their market cap soared thanks to the success of their key drug. This chart clearly shows how the market values a potential blockbuster. This value is not based on the company's staff, but on the intellectual property created by a small team of scientists and doctors.
%20of%20the%20company%20Karuna%20Therapeutics%20(KRTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Karuna-Therapeutics-KRTX&v=1772648045455 "Chart of market capitalization per employee (in thousands of dollars) of the company Karuna Therapeutics (KRTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Karuna Therapeutics develops innovative drugs for the treatment of mental illnesses, particularly schizophrenia. Its valuation is driven by the enormous potential of its lead drug, KarXT. This chart shows how investors value this potential blockbuster based on the relatively small team behind the development.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772648045476 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Karuna Therapeutics is a biopharmaceutical company whose lead drug has demonstrated breakthrough results in the treatment of schizophrenia. The chart reflects the valuation of a potential blockbuster. The very high market capitalization per employee demonstrates investors' belief that the team has created a drug capable of changing the standard of treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648045501 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Karuna Therapeutics (KRTX)
Karuna (acquired by BMY) is a biotech company that developed a breakthrough drug (KarXT) for schizophrenia (with a novel mechanism of action). The company was unprofitable. This chart shows the net loss (R&D costs) per scientist who developed this blockbuster.
%20Chart%20Karuna%20Therapeutics%20(KRTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Karuna-Therapeutics-KRTX&v=1772648045506 "Company Profit Per Employee (in thousands of dollars) Chart Karuna Therapeutics (KRTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Karuna Therapeutics is a biotech company that developed the breakthrough drug KarXT for schizophrenia, which was recently acquired by Bristol Myers Squibb. This chart reflects the team's performance in conducting clinical trials and securing approval. It serves as a benchmark demonstrating how a small team can create enormous value in biotech.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772648045530 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Karuna Therapeutics (recently acquired by $BMY) is a biopharmaceutical company that achieved a breakthrough in the treatment of schizophrenia with its drug KarXT. Prior to approval, it was an R&D company. This graph (pre-acquisition) would reflect the loss per employee typical for a biotech investing billions in clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648045540 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Karuna Therapeutics (KRTX)
Karuna Therapeutics is a biotech company that has successfully developed a treatment for schizophrenia. This graph will reflect the commercial launch of its breakthrough product. The sharp increase in revenue per employee demonstrates the drug's enormous market potential and the effectiveness of a small team during the initial sales phase.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Karuna-Therapeutics-KRTX&v=1772648045575 "Sales chart per company employee Karuna Therapeutics (KRTX)")
Sales per employee in the market segment - Pharma psycho
Karuna Therapeutics (KRTX) was a biotech company (acquired by Bristol Myers Squibb) that developed a breakthrough drug (KarXT) for the treatment of schizophrenia. At the time of the acquisition, they had no revenue. This graph didn't reflect their value. Their staff productivity was zero, but their value lay in the potential of their R&D platform.
Sales per employee for the market as a whole
Karuna Therapeutics is a biotech company focused on psychiatry and neurology. At the R&D stage, this indicator reflects investment in the future. A team of scientists is working on developing a platform, and this indicator will only increase with the success of clinical trials and the commercialization of their research.
Short shares by company, segment and market as a whole
Shares shorted by company Karuna Therapeutics (KRTX)
Karuna Therapeutics (KRTX) is a biotech company that has achieved a breakthrough in the treatment of schizophrenia with its drug KarXT, which works through a novel mechanism (muscarinic receptors). This chart shows bearish bets. Are the bears doubting the drug's commercial potential or the success of its market launch?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Karuna-Therapeutics-KRTX&v=1772648045641 "Short Shares Chart for the Company Karuna Therapeutics (KRTX)")
Shares shorted by market segment - Pharma psycho
Karuna Therapeutics is a biopharmaceutical company that has successfully developed a new class of drugs for the treatment of schizophrenia. This chart illustrates the overall bearish sentiment in the psychiatric (CNS) biotech sector. It reflects the overall investor confidence in this challenging segment, where many companies have failed, providing a backdrop for assessing Karuna's success.
Shares shorted by the overall market
Karuna Therapeutics focuses on psychiatry and neurology. While its developments are promising, drug development requires capital. This indicator of market risk aversion highlights the vulnerability of even promising biotechs, as fear can block access to funding for late-stage development.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Karuna Therapeutics (KRTX)
Karuna is the biotech company behind KarXT, one of the most anticipated breakthroughs in schizophrenia treatment. This chart is a "pulse" of excitement. The "temperature" of investor interest has "overheated" to an all-time high and then plateaued. This reflects the news of the company's $14 billion acquisition by Bristol-Myers Squibb, a bet on their blockbuster drug.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Karuna-Therapeutics-KRTX&v=1772648045683 "RSI 14 indicator chart for the company's stock Karuna Therapeutics (KRTX)")
RSI 14 Market Segment - Pharma psycho
Karuna Therapeutics is a "biotech" company, a "breakthrough" in *psychiatry*. Their drug (KarXT) is a *new* mechanism for treating *schizophrenia* (acquired by Bristol Myers Squibb). The "Pharma psycho" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It helps us understand: was the acquisition of Karuna due to their R&D or the *general* "hype" in the sector?
RSI 14 for the overall market
For Karuna Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KRTX (Karuna Therapeutics)
Karuna Therapeutics (acquired by Bristol Myers Squibb) is the biotech company behind the breakthrough drug KarXT for schizophrenia. This chart shows the average analyst forecast. Their targets were based on an assessment of KarXT's enormous market potential, trial data, and, ultimately, the BMY deal price.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KRTX-Karuna-Therapeutics&v=1772648046025 "A chart showing analyst consensus forecasts for the expected stock price. KRTX (Karuna Therapeutics)")
The difference between the consensus estimate and the actual stock price KRTX (Karuna Therapeutics)
Karuna is a "breakthrough" in psychiatry. Their drug (KarXT) is the first *new* treatment for schizophrenia in decades, promising to change everything. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, which is now tied to the acquisition price of the giant BMS.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KRTX-Karuna-Therapeutics&v=1772648046069 "A chart showing the difference between the consensus forecast and the actual stock price. KRTX (Karuna Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Karuna (KRTX) is a biotech company that developed KarXT, a potentially revolutionary (non-dopamine) drug for the treatment of schizophrenia. This chart shows the overall expectations for the psychopharma sector, reflecting whether experts believe this will be the first "real" breakthrough in the treatment of this complex disorder in 50 years.
Analysts' consensus forecast for the overall market share price
Karuna Therapeutics (KRTX) is a breakthrough biotech company. Their drug, KarXT, is the first *fundamentally new* class of drugs to treat schizophrenia in 50 years. This chart shows the overall risk appetite, reflecting how much the market values genuine scientific innovations that solve major medical problems (the company was acquired by BMY).
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Karuna Therapeutics
Karuna is an absolute blockbuster in psychiatric R&D. It's a biotech company that proved (in R&D) that their drug (KarXT) treats schizophrenia (via a novel mechanism) and was acquired by Bristol-Myers (BMY) for $14 billion. This chart is a summary of their (triumphant) R&D journey. It reflects their (successful) data and the (massive) M&A premium.
AKIMA Market Segment Index - Pharma psycho
Karuna (KRTX) is a breakthrough psychotherapy pharma. They are developing KarXT, potentially the first revolutionary drug for schizophrenia in decades. It's a blockbuster in R&D. This chart compares their composite index to the sector average.
The AKIM Index for the overall market
Karuna Therapeutics, a biotech company that developed KarXT, a new class of drugs for schizophrenia, was acquired by Bristol Myers Squibb. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this major success in neuroscience compares to overall economic trends.
